Sunday , June 4 2023

$ -0,30 EPS expected by Intec Pharma Ltd. (NTEC)


<! –

Trending Stock News


November 10, 2018 – Nellie Frank

Intec Pharma Ltd. (NASDAQ: NTEC) Logo

Analysts expect Intec Pharma Ltd. (NASDAQ: NTEC) will report a $ -0.30 EPS on November 21st. They provide an $ 0.10 EPS change or 25.00% of the last quarter's $ -0.4 EPS. Upon deposit of $ -0.34 EPS, Intec Pharma Ltd. analysts believe that EPS growth is -11.76%. During the last trading session, the stock price went up by 0.17% or $ 0.01, reaching $ 5.89. About 126,488 traded shares. From November 11, 2007, Intec Pharma Ltd. (NASDAQ: NTEC) has fallen by 49.01% since November 11, 2017 and has fallen. S & P500 has slightly improved by 64.63%.

Intec Pharma Ltd., a clinical phase biopharmaceutical company, focuses on drug development based on its patented Acordion Pill platform technology in Israel. The company has a market cap of $ 195.70 million. Accordion Pill is an oral delivery system designed to improve the efficacy and safety of existing medicines and medicines through gastric retention and a specific release mechanism. There are currently negative earnings. The company's main product candidate is accordion tablets Carbidopa / Levodopa, which is a Phase III clinical study for the treatment of Parkinson's disease in patients with advanced Parkinson's disease.

Newer Intec Pharma Ltd. (NASDAQ: NTEC) news was published on:, which came out: "Intec Pharma completed its registration in the AP-CD / LD Phase 3 study on advanced PD treatment on October 22, 2018." also posted news titled "Intec Pharma Reports Third Quarter 2018 Financial Results and Corporate Updates" in November 2018. news article entitled: "Intec Pharma: Leading Program Moves On, Moves Forward" with Release Date: October 26, 2018 was also interesting.

Intec Pharma Ltd. (NASDAQ: NTEC) Ratings Chart

– Enter your email address below to receive a concise summary daily newsletter and analytics ratings with our FREE daily email newsletter.

Nellie Frank

Source link